UFP Technologies, Inc. — Q3 2016 Form 10-Q
Business context and reporting period. UFP Technologies designs and manufactures converted foam, plastic, composite, and natural-fiber products, serving medical, automotive, consumer, electronics, industrial, and aerospace and defense markets. This unaudited report covers the three and nine months ended September 30, 2016; comparisons are with the corresponding 2015 periods. The company reports one operating segment.
Financial results
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Net sales | $37.22M | $34.44M | $109.63M | $104.92M |
| Gross profit / margin | $8.45M / 22.7% | $9.51M / 27.6% | $26.47M / 24.1% | $28.44M / 27.1% |
| Operating income | $4.08M | $3.06M | $9.98M | $9.11M |
| Net income | $2.67M | $1.99M | $6.48M | $5.92M |
| Diluted EPS | $0.37 | $0.28 | $0.89 | $0.82 |
| Operating cash flow | Not separately presented for quarter | $6.58M | $9.25M |
Q3 sales rose 8.1%; nine-month sales rose 4.5%. Despite higher sales, gross margin fell 4.9 percentage points in Q3 and 3.0 points year to date. Management attributed the pressure principally to consolidation-related manufacturing inefficiencies and customer part requalification, including higher material, labor, and overhead costs. Nine-month results also included a roughly $288,000 write-off of obsolete tooling and inventory.
Operating income and net income included a $1.68M Q3 and $2.11M nine-month gain from a polyurethane-foam antitrust settlement. Restructuring costs declined to $25,000 in Q3 and $203,000 for nine months, compared with $851,000 and approximately $959,000, respectively, in 2015. The settlement and lower restructuring expense are important context when assessing reported earnings growth.
Liquidity, debt, and balance sheet
- At September 30, 2016, cash and equivalents were $30.12M, versus $29.80M at December 31, 2015. Current assets were $69.64M and current liabilities $11.51M.
- Total debt was approximately $1.11M: $1.03M current and $0.08M long-term. The company had no borrowings on its $40M revolving credit facility and reported compliance with its covenants. The facility matures November 30, 2018.
- Nine-month operating cash flow of $6.58M was below the prior-year $9.25M, with receivables increasing $4.83M, partly attributed to strong September sales. Investing cash outflow was $6.07M, primarily for manufacturing equipment and the Newburyport facility. Financing cash outflow was $0.19M.
- Capital expenditures were $6.08M for the first nine months. Management expected available resources, operating cash flow, and credit and equipment financing to meet requirements for the next twelve months; this expectation depends on future operating performance.
Business trends, outlook, and risks
- Q3 growth was led by medical, consumer, and automotive markets; aerospace and defense and electronics were weaker. Medical sales benefited from a new five-year customer contract and broader demand. Medical represented 44.3% of Q3 sales.
- Management anticipated continued medical-market sales growth and expected gross margins to improve as employees gain training and transferred parts are requalified. No specific revenue or earnings guidance was provided.
- Management expected approximately $1.0M in annual savings from Massachusetts plant consolidations. Approximately $1.9M of an estimated $2.1M in consolidation costs had been incurred through September 30, 2016. Consolidation-related inefficiencies and requalification delays could defer savings or constrain production.
- Other disclosed uncertainties include customer-contract execution, acquisition identification and integration, equipment implementation and utilization, and changing demand across end markets. The company reported no material changes to previously disclosed risk factors, market risks, contractual obligations, or internal control over financial reporting. It had no off-balance-sheet arrangements other than operating leases.
- The company was evaluating a new share-based compensation accounting standard expected to apply beginning in 2017. A roughly $40,000 jurisdictional tax assessment increased the nine-month effective tax rate to 35.4%, from 35.0%.
Most important facts for investors to verify
- Whether gross margins recover as management expects, and the pace and cost of customer part requalifications and plant consolidation.
- How much reported earnings growth reflects core operations versus the one-time $2.11M settlement gain and reduced restructuring charges.
- Receivables and working-capital trends, given the $4.83M nine-month increase in receivables and lower operating cash flow year over year.
- Whether the projected $1.0M annual consolidation savings are realized and whether remaining costs stay within the estimate.
- Future capital spending, revolving-credit availability and covenant compliance, and the company’s ability to sustain cash generation.